Evidence map›Paper›PMID 37922691›Full record

Trial reportESMO open2023

Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816.

C Wang, K-N Chen, Q Chen, L Wu, Q Wang, X Li, K Ying, W Wang, J Zhao, L Liu and 9 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07632365 (A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Induction Chemoimmunotherapy Followed by Concurrent Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07632365 phase1 / phase2recruitingnot on this map

A Phase I/II Multicenter Study Evaluating the Safety and Efficacy of Induction Chemoimmunotherapy Followed by Concurrent Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

TypeinterventionalSponsorShanghai Chest HospitalRan2022 to 2028Enrolled108ConditionsNon-Small Cell Lung Cancer, Locally Advanced Non-Small Cell Lung Cancer, Unresectable Stage III NSCLCArmsInduction chemoimmunotherapy, Concurrent chemoradiotherapy (cCRT), consolidation immunotherapy
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Peripheral blood inflammatory markers as predictive and prognostic indicators in neoadjuvant immunotherapy for non-small cell lung cancer.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 2 countries.

C WangTianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: wangchangli@tjmuch.com.
K-N ChenPeking University Cancer Hospital and Institute, Beijing, China.
Q ChenCancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
L WuHunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Q WangZhongshan Hospital and Fudan University, Shanghai, China.
X LiTangdu Hospital, Xi'an, China.
K YingSir Run Run Shaw Hospital, Hangzhou, China.
W WangHunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
J ZhaoCancer Center of Guangzhou Medical University, Guangzhou, China.
L LiuWest China Hospital of Sichuan University, Chengdu, China.
J FuThe First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
C ZhangXiangya Hospital of Central South University, Changsha, China.
J LiuThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Y HuChinese People's Liberation Army General Hospital (301 Hospital), Beijing, China.
I NtambweBristol Myers Squibb, Princeton, NJ, USA.
J CaiBristol Myers Squibb, Princeton, NJ, USA.
J BushongBristol Myers Squibb, Princeton, NJ, USA.
P TranBristol Myers Squibb, Princeton, NJ, USA.
S LuShanghai Chest Hospital and Shanghai Jiao Tong University, Shanghai, China. Electronic address: shun_lu@hotmail.com.
Bristol-Myers Squibb (United States) · USCentral South University · CNChinese People’s Liberation Army 263 hospital · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNGuangzhou Medical University · CNHunan Cancer Hospital · CNNanchang University · CNPeking University · CNShanghai Chest Hospital · CNSir Run Run Shaw Hospital · CNSun Yat-sen University · CNTang Du Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNWest China Hospital of Sichuan University · CNXiangya Hospital Central South University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant nivolumab plus chemotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) versus chemotherapy alone in patients with resectable non-small-cell lung cancer (NSCLC) in the global phase III CheckMate 816 study. Here, we report post hoc exploratory efficacy, safety, and surgical outcomes in the Chinese subpopulation of this study.

methodsAdults with stage IB-IIIA resectable NSCLC were randomized to receive nivolumab 360 mg plus chemotherapy or chemotherapy alone every 3 weeks for three cycles followed by surgery. Primary endpoints included EFS and pCR (both per blinded independent review). EFS and pCR results were from 14 October 2022, and 16 September 2020, database locks, respectively.

resultsThe Chinese subpopulation comprised 97 patients (nivolumab plus chemotherapy, 44; chemotherapy, 53). At 38.2 months of minimum follow-up, median EFS was not reached [95% confidence interval (CI) 23.4 months-not reached] in the nivolumab plus chemotherapy arm and 13.9 months (95% CI 8.3-34.3 months) in the chemotherapy arm (hazard ratio 0.47, 95% CI 0.25-0.88). pCR rates were 25.0% (95% CI 13.2% to 40.3%) and 1.9% (95% CI 0.0% to 10.1%), respectively (odds ratio 11.05; 95% CI 1.41-86.49). Of 97 Chinese patients, 36 (82%) in the nivolumab plus chemotherapy arm and 41 (77%) in the chemotherapy arm underwent definitive surgery. Grade 3-4 treatment-related adverse events occurred in 18/43 patients (42%) treated with nivolumab plus chemotherapy and 22/53 patients (42%) treated with chemotherapy.

conclusionsConsistent with findings in the global study population of CheckMate 816, neoadjuvant nivolumab plus chemotherapy improved EFS and pCR versus chemotherapy in the Chinese subpopulation without impacting treatment tolerability or the feasibility of surgery. These findings support the use of nivolumab plus chemotherapy as a standard neoadjuvant treatment option for Chinese patients with resectable NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultChinaHumansNeoadjuvant TherapyNivolumabPathologic Complete ResponseNivolumabChinaimmune checkpoint inhibitorsimmunotherapynon-small-cell lung cancersubgroup analysis

Identifiers

PMID37922691
PMCPMC10774966
OpenAlexW4388165174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.